Globus Medical Inc (GMED) shareholders
Close on Nov 18, 2026Market cap $9.47BP/E 18.0Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Sonali Paul Joint filing with David C. Paul (15.76%) | 22,087,897 | 16.24% | 13G (passive) amendment | Dec 31, 2023 |
| BlackRock, Inc. | 10,704,283 | 8.00% | 13G (passive) amendment | Sep 30, 2026 |
| Janus Henderson Group PLC | 7,029,294 | 6.10% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GMED | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,806,724 | 8.05% | $853.84M | +309,310 | 0.01% |
| Jupiter Topco LLC | 8,200,423 | 6.11% | $647.93M | New | 0.26% |
| Vanguard Capital Management LLC | 5,107,532 | 3.80% | $403.55M | +74,800 | 0.01% |
| Vanguard Portfolio Management LLC | 4,994,385 | 3.72% | $394.61M | +114,926 | 0.02% |
| Invesco Ltd. | 4,309,771 | 3.21% | $340.52M | −6,883 | 0.03% |
| Kayne Anderson Rudnick Investment Management LLC | 4,279,730 | 3.19% | $338.14M | New | 1.05% |
| State Street Corp | 3,714,029 | 2.77% | $293.54M | +123,657 | 0.01% |
| Sculptor Capital LP | 3,000,000 | 2.23% | $237.03M | −58,000 | 1.93% |
| JPMorgan Chase & Co | 2,743,850 | 2.04% | $230.76M | +148,542 | 0.01% |
| Bank Of Montreal /Can/ | 2,425,491 | 1.81% | $191.64M | +118,310 | 0.06% |
| Alliancebernstein L.P. | 2,380,344 | 1.77% | $205.09M | +629,512 | 0.07% |
| Dimensional Fund Advisors LP | 2,369,310 | 1.76% | $187.25M | +599,413 | 0.03% |
| Geode Capital Management, LLC | 2,153,014 | 1.60% | $170.15M | +40,890 | 0.01% |
| Goldman Sachs Group Inc | 1,781,608 | 1.33% | $140.76M | +649,446 | 0.01% |
| Arrowstreet Capital, Limited Partnership | 1,716,621 | 1.28% | $135.63M | +803,716 | 0.06% |
| Boston Trust Walden Corp | 1,573,361 | 1.17% | $124.31M | +318,451 | 0.95% |
| Allspring Global Investments Holdings, LLC | 1,571,681 | 1.17% | $119.38M | +1,143,641 | 0.18% |
| Boston Partners | 1,554,990 | 1.16% | $122.85M | New | 0.11% |
| GW&K Investment Management, LLC | 1,453,206 | 1.08% | $114.82M | −41,517 | 0.90% |
| Geneva Capital Management LLC | 1,417,067 | 1.06% | $111.96M | −343,904 | 2.57% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 597 | 119M | 88.9% | 83 / 252 | 181 / 86 | 29M | 12M |
| Q1 2026 | 607 | 110M | 81.6% | 108 / 231 | 183 / 53 | 22M | 14M |
| Q4 2025 | 563 | 112M | 83.6% | 132 / 150 | 221 / 50 | 20M | 22M |
| Q3 2025 | 490 | 120M | 89.1% | 80 / 173 | 177 / 64 | 22M | 17M |
| Q2 2025 | 481 | 115M | 85.8% | 67 / 195 | 150 / 94 | 19M | 13M |
| Q1 2025 | 513 | 110M | 81.9% | 92 / 204 | 143 / 68 | 14M | 12M |
| Q4 2024 | 500 | 109M | 81.1% | 104 / 168 | 154 / 43 | 14M | 15M |
| Q3 2024 | 449 | 111M | 82.5% | 54 / 147 | 175 / 52 | 16M | 12M |
| Q2 2024 | 450 | 117M | 87.0% | 69 / 136 | 167 / 55 | 12M | 12M |
| Q1 2024 | 438 | 117M | 87.1% | 72 / 143 | 150 / 42 | 16M | 10M |
| Q4 2023 | 408 | 111M | 82.5% | 52 / 134 | 161 / 65 | 17M | 16M |
| Q3 2023 | 431 | 109M | 81.5% | 92 / 210 | 74 / 41 | 36M | 8M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
489 funds held GMED in Q2 2026, 41% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of GMED | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 3,877,935 | 2.89% | $306.40M | 0.25% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,595,564 | 2.68% | $284.09M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,597,815 | 1.93% | $205.25M | 0.11% | Jun 30, 2026 |
| Janus Henderson Enterprise Fund | 2,207,141 | 1.64% | $174.39M | 0.78% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,496,500 | 1.11% | $118.24M | 0.25% | Jun 30, 2026 |
| JPMorgan Mid Cap Value Fund | 1,475,978 | 1.10% | $116.62M | 1.04% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,299,484 | 0.97% | $102.67M | 0.11% | Jun 30, 2026 |
| Allspring Special Mid Cap Value Fund | 1,234,495 | 0.92% | $97.54M | 0.72% | Jun 30, 2026 |
| Janus Henderson Triton Fund | 1,111,347 | 0.83% | $87.81M | 1.48% | Jun 30, 2026 |
| Disciplined Value Mid Cap Fund | 1,030,725 | 0.77% | $81.44M | 0.35% | Jun 30, 2026 |
| Invesco Small Cap Value Fund | 1,012,359 | 0.75% | $79.76M | 0.72% | Jul 31, 2026 |
| Invesco Value Opportunities Fund | 825,032 | 0.61% | $65.00M | 0.71% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 744,421 | 0.55% | $58.82M | 1.01% | Jun 30, 2026 |
| Fullerthaler Behavioral Small-Cap Growth | 738,600 | 0.55% | $58.36M | 0.94% | Jun 30, 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 678,028 | 0.51% | $53.57M | 0.47% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David C. Paul | Executive Chairman, Director, 10% owner | 23,087,808 | 17.20% | Jan 23, 2026 |
| Keith W. Pfeil | President, CEO, Director | 5,833 | 0.00% | Jan 23, 2026 |
| Daniel T. Scavilla | President, CEO, Director | 0 | – | Mar 28, 2025 |
| Kelly Huller | EVP, GC, Corporate Secretary | 0 | – | Feb 27, 2026 |
| Kyle Kline | Senior Vice President, CFO | 0 | – | Jan 23, 2026 |
| James R. Tobin | Director | 0 | – | Nov 12, 2026 |
| Ann D. Rhoads | Director | 35,384 | 0.03% | Nov 5, 2026 |
| Stephen T. Zarrilli | Director | 25,000 | 0.02% | Aug 19, 2026 |
| David D. Davidar | Director | 673,642 | 0.50% | Jul 28, 2026 |
| Robert Andrew Douglas | Director | 2,005 | 0.00% | Jan 23, 2026 |
| Leslie V. Norwalk | Director | 10,419 | 0.01% | Jan 23, 2026 |
| Dan Wolterman | Director | 24,025 | 0.02% | Jan 23, 2026 |
| John A. DeFord | Director | 15,578 | 0.01% | Jan 23, 2026 |
| Dan Lemaitre | Director | 1,097 | 0.00% | Jan 23, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James R. Tobin Director | Nov 10, 2026 | Sale | −4,004 | $75.68 | $303.04K | 0 |
| James R. Tobin Director | Nov 10, 2026 | Sale | −37,662 | $75.10 | $2.83M | 4,004 |
| James R. Tobin Director | Nov 10, 2026 | Option exercise | +5,208 | $43.58 | $226.96K | 41,666 |
| James R. Tobin Director | Nov 10, 2026 | Option exercise | +21,458 | $53.27 | $1.14M | 36,458 |
| James R. Tobin Director | Nov 10, 2026 | Option exercise | +15,000 | $65.05 | $975.75K | 15,000 |
| Ann D. Rhoads Director | Nov 4, 2026 | Sale(10b5-1 plan) | −5,000 | $85.00 | $425.00K | 35,384 |
| James R. Tobin Director | Sep 15, 2026 | Sale | −30,000 | $74.58 | $2.24M | 0 |
| James R. Tobin Director | Sep 15, 2026 | Option exercise | +15,000 | $63.68 | $955.20K | 30,000 |
| James R. Tobin Director | Sep 15, 2026 | Option exercise | +15,000 | $53.75 | $806.25K | 15,000 |
| Stephen T. Zarrilli Director | Aug 18, 2026 | Option exercise | +25,000 | $53.27 | $1.33M | 25,000 |
| Stephen T. Zarrilli Director | Aug 18, 2026 | Sale | −25,000 | $87.04 | $2.18M | 0 |
| David D. Davidar Director | Jul 27, 2026 | Gift | −2,500 | – | – | 507,675 |
| David D. Davidar Director | Jun 5, 2026 | Sale | −25,000 | $80.76 | $2.02M | 510,175 |
| David D. Davidar Director | Jun 5, 2026 | Option exercise | +25,000 | $26.27 | $656.75K | 535,175 |
| Ann D. Rhoads Director | Jun 4, 2026 | Option exercise | +25,000 | $26.27 | $656.75K | 40,384 |
| Kelly Huller EVP, GC, Corporate Secretary | Feb 25, 2026 | Sale(10b5-1 plan) | −20,000 | $94.50 | $1.89M | 0 |
| Kelly Huller EVP, GC, Corporate Secretary | Feb 25, 2026 | Option exercise | +20,000 | $43.58 | $871.60K | 20,000 |
| Kelly Huller EVP, GC, Corporate Secretary | Feb 12, 2026 | Sale(10b5-1 plan) | −10,000 | $87.67 | $876.70K | 0 |
| Kelly Huller EVP, GC, Corporate Secretary | Feb 12, 2026 | Option exercise | +10,000 | $45.64 | $456.40K | 10,000 |
| Leslie V. Norwalk Director | Jan 8, 2026 | Sale(10b5-1 plan) | −2,000 | $101.10 | $202.20K | 10,419 |
| Kyle Kline Senior Vice President, CFO | Jan 8, 2026 | Sale(10b5-1 plan) | −3,594 | $101.10 | $363.35K | 0 |
| Kyle Kline Senior Vice President, CFO | Jan 8, 2026 | Option exercise | +3,594 | $51.87 | $186.42K | 3,594 |
| Leslie V. Norwalk Director | Dec 12, 2025 | Sale(10b5-1 plan) | −4,000 | $88.85 | $355.40K | 12,419 |
| David C. Paul Executive Chairman, Director, 10% owner | Dec 8, 2025 | Option exercise | +34,375 | $25.52 | $877.25K | 60,417 |
| Kyle Kline Senior Vice President, CFO | Dec 1, 2025 | Sale(10b5-1 plan) | −18,542 | $90.00 | $1.67M | 0 |
| Kyle Kline Senior Vice President, CFO | Dec 1, 2025 | Option exercise | +4,896 | $63.68 | $311.78K | 18,542 |
| Kyle Kline Senior Vice President, CFO | Dec 1, 2025 | Option exercise | +5,000 | $64.44 | $322.20K | 13,646 |
| Kyle Kline Senior Vice President, CFO | Dec 1, 2025 | Option exercise | +5,000 | $56.43 | $282.15K | 8,646 |
| Kyle Kline Senior Vice President, CFO | Dec 1, 2025 | Option exercise | +3,646 | $53.14 | $193.75K | 3,646 |
| Kelly Huller SVP, GC, Corporate Secretary | Nov 25, 2025 | Option exercise | +7,500 | $25.96 | $194.70K | 7,500 |
| Kelly Huller SVP, GC, Corporate Secretary | Nov 25, 2025 | Sale(10b5-1 plan) | −7,500 | $90.00 | $675.00K | 0 |
| David D. Davidar Director | Nov 12, 2025 | Sale | −25,000 | $86.00 | $2.15M | 516,275 |
| David D. Davidar Director | Nov 12, 2025 | Option exercise | +25,000 | $25.52 | $638.00K | 541,275 |
| Stephen T. Zarrilli Director | Nov 11, 2025 | Sale | −25,000 | $84.29 | $2.11M | 0 |
| Stephen T. Zarrilli Director | Nov 11, 2025 | Option exercise | +25,000 | $44.14 | $1.10M | 25,000 |
| Ann D. Rhoads Director | Nov 10, 2025 | Sale(10b5-1 plan) | −2,000 | $85.00 | $170.00K | 15,384 |
| Ann D. Rhoads Director | Nov 7, 2025 | Sale(10b5-1 plan) | −8,000 | $81.00 | $648.00K | 17,384 |
| Ann D. Rhoads Director | Sep 15, 2025 | Sale(10b5-1 plan) | −10,000 | $58.46 | $584.60K | 25,384 |
| Ann D. Rhoads Director | Feb 28, 2025 | Sale(10b5-1 plan) | −7,500 | $78.68 | $590.10K | 35,384 |
| Keith W. Pfeil COO, CFO | Jan 10, 2025 | Option exercise | +5,833 | $49.65 | $289.61K | 5,833 |
| Keith W. Pfeil COO, CFO | Jan 10, 2025 | Sale(10b5-1 plan) | −12,501 | $88.17 | $1.10M | 1,666 |
| Keith W. Pfeil COO, CFO | Jan 10, 2025 | Sale(10b5-1 plan) | −1,666 | $89.17 | $148.56K | 0 |
| Keith W. Pfeil COO, CFO | Jan 10, 2025 | Option exercise | +8,334 | $53.27 | $443.95K | 14,167 |
| David D. Davidar Director | Jan 2, 2025 | Gift | −6,100 | – | – | 510,175 |
| Kelly Huller SVP, GC, Corporate Secretary | Dec 2, 2024 | Option exercise | +2,500 | $24.21 | $60.53K | 2,500 |
| Kelly Huller SVP, GC, Corporate Secretary | Dec 2, 2024 | Sale(10b5-1 plan) | −2,500 | $87.00 | $217.50K | 0 |
| David D. Davidar Director | Nov 22, 2024 | Sale(10b5-1 plan) | −6,766 | $85.00 | $575.11K | 516,275 |
| David D. Davidar Director | Nov 22, 2024 | Sale(10b5-1 plan) | −6,746 | $85.00 | $573.41K | 165,967 |
| Dan Lemaitre Director | Nov 22, 2024 | Option exercise | +1,097 | $65.05 | $71.36K | 1,097 |
| Dan Lemaitre Director | Nov 22, 2024 | Sale | −1,097 | $85.02 | $93.27K | 0 |
| David D. Davidar Director | Nov 21, 2024 | Sale(10b5-1 plan) | −13,234 | $85.00 | $1.12M | 523,041 |
| David D. Davidar Director | Nov 21, 2024 | Sale(10b5-1 plan) | −13,254 | $85.00 | $1.13M | 172,713 |
| Dan Lemaitre Director | Nov 21, 2024 | Sale | −13,278 | $85.00 | $1.13M | 0 |
| Dan Lemaitre Director | Nov 21, 2024 | Option exercise | +13,278 | $65.05 | $863.73K | 13,278 |
| Daniel T. Scavilla President, CEO, Director | Nov 21, 2024 | Sale(10b5-1 plan) | −130,000 | $85.00 | $11.05M | 0 |
| Daniel T. Scavilla President, CEO, Director | Nov 21, 2024 | Option exercise | +80,000 | $43.58 | $3.49M | 130,000 |
| Daniel T. Scavilla President, CEO, Director | Nov 21, 2024 | Option exercise | +50,000 | $43.77 | $2.19M | 50,000 |
| David C. Paul Executive Chairman, Director, 10% owner | Nov 15, 2024 | Option exercise | +26,042 | $24.10 | $627.61K | 26,042 |
| Daniel T. Scavilla President, CEO, Director | Nov 6, 2024 | Option exercise | +30,000 | $26.27 | $788.10K | 30,000 |
| Daniel T. Scavilla President, CEO, Director | Nov 6, 2024 | Option exercise | +30,000 | $43.77 | $1.31M | 60,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Globus Medical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 66,330 shares on Sep 10, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| James R. Tobin Director | Nov 10, 2026 | 41,666 | $3.13M | Nov 10, 2026 | Cashless Stock Option Exercise |
| Ann D. Rhoads Director | Nov 4, 2026 | 5,000 | $425.00K | Nov 4, 2026 | Stock Option Exercise |
| James R. Tobin Director | Sep 15, 2026 | 30,000 | $2.24M | Sep 15, 2026 | Cashless Option Exercise |
| Stephen T. Zarrilli Director | Aug 18, 2026 | 25,000 | $2.18M | Aug 18, 2026 | Cashless Option Exercise |
| David D. Davidar Director | Jun 5, 2026 | 25,000 | $2.03M | Jun 5, 2026 | Cashless Option Exercise |
| John A. DeFord Former Director | Apr 14, 2026 | 30,000 | $2.79M | Apr 14, 2026 | Cashless Stock Option |
| Kelly Huller Officer | Feb 25, 2026 | 20,000 | $1.89M | Feb 25, 2026 | Cashless Stock Option Exercise |
| Kelly Huller Officer | Feb 12, 2026 | 10,000 | $876.00K | Feb 12, 2026 | Cashless Option Exercise |
| Kyle Kline Officer | Jan 8, 2026 | 3,594 | $363.17K | Jan 8, 2026 | CASHLESS OPTION EXERCISE |
| Leslie V. Norwalk Director | Jan 8, 2026 | 2,000 | $202.00K | Jan 8, 2026 | RSU Vesting |
| Leslie V. Norwalk Director | Dec 12, 2025 | 4,000 | $355.00K | Dec 12, 2025 | RSU Vesting |
| Kyle Kline Officer | Dec 1, 2025 | 18,542 | $1.67M | Dec 1, 2025 | Cashless Stock Option Exercise |
| Kelly Huller Officer | Nov 25, 2025 | 7,500 | $675.00K | Nov 25, 2025 | Cashless Stock Option Exercise |
| Stephen T. Zarrilli Director | Nov 12, 2025 | 25,000 | $2.11M | Nov 11, 2025 | Cashless Stock Option Exercise |
| David D. Davidar Director | Nov 12, 2025 | 25,000 | $2.15M | Nov 12, 2025 | Cashless Option Exercise |
Congress trades
12 trades in Globus Medical reported by 5 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | Bought | Sep 3, 2026 | $1K–15K | Oct 12, 2026 |
| Gilbert Cisneros CA31 | Bought | Aug 19, 2026 | $15K–50K | Sep 10, 2026 |
| Gilbert Cisneros CA31 | Bought | Mar 3, 2026 | $1K–15K | Apr 7, 2026 |
| Lisa McClain MI09 · spouse | Sold | Jul 10, 2025 | $1K–15K | Aug 13, 2025 |
| Lisa McClain MI09 · spouse | Sold (part) | Jun 24, 2025 | $1K–15K | Aug 13, 2025 50 days late |
| Lisa McClain MI09 · spouse | Bought | Jun 17, 2025 | $1K–15K | Aug 13, 2025 57 days late |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Apr 9, 2025 | $1K–15K | May 14, 2025 |
| Josh Gottheimer NJ05 · joint account | Bought | Apr 3, 2023 | $1K–15K | May 19, 2023 46 days late |
| Daniel Goldman NY10 | Sold | Mar 6, 2023 | $15K–50K | Apr 17, 2023 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Feb 8, 2023 | $1K–15K | Mar 17, 2023 |
| Josh Gottheimer NJ05 · joint account | Sold (part) | Jan 11, 2023 | $1K–15K | Feb 17, 2023 |
| Lois Frankel FL22 | Bought | Oct 6, 2016 | $1K–15K | Oct 21, 2016 |
See a number that looks wrong?